Vigo Health begins clinical testing in cooperation with Riga Stradins University

digital therapy solution

SIA “Vigo Health” in cooperation with Riga Stradiņš University (RSU) starts the clinical testing of a digital therapy solution for stroke survivors, the first of its kind in Latvia. Stroke is the leading cause of death and disability worldwide, resulting in consuming a significant 34% of the overall healthcare costs.

The Latvia-based digital therapy company Vigo Health today announced the launch of a new study in collaboration with RSU to evaluate the clinical and cost-effectiveness of using “Vigo” – digital therapy tool that helps recover and deal with the consequences of stroke. 

Vigo Health provides remote therapy software “Vigo” that helps patients overcome functional, cognitive and emotional consequences at the comfort of their own home. Already now it has helped more than 100 stroke survivors. Like all medical interventions, “Vigo” needs to be built on a solid evidence base of its medical and economic effectiveness. That is the reason the clinical testing process has been launched – the clinical testing is divided into several stages and the first phase of the study is currently initiated.

“This is a historic moment. For the first time in Latvia a clinical study is being conducted on a digital therapy solution, moreover it is also one that originates from Latvia. RSU and Vigo Health have already collaborated on research before, as RSU has excellent specialists and infrastructure for such research, ” comments Dr. Jānis Šlēziņš, neurosurgeon and a co-founder of Vigo Health.

In reality, satisfactory medical care is not available for most people in the world. The number of such people is growing, also including in countries better off. Global trends are:

· World population growth;

· Increase in life expectancy;

· Increase in the number of cases of chronic diseases;

· Raise in the treatment quality standard;

· The growing shortage of human resources in medicine;

· Continuous increase in medical costs;

· Occupancy of existing medical resources with pandemics (Covid-19, SARS, Ebola, H1N1, etc.).

In the light of these trends, healthcare providers and payers are looking for ways to make healthcare better, cheaper and more accessible. Understandably, with the existing healthcare organization based on the work of human specialists, this goal is far out of reach. The way to solve this would be by increasing focus on technological solutions, therefore making it easier for professionals to focus on treating patients with more complex conditions.

One ray of hope is the so-called Digital Therapeutics (DTx) or Software as a medical device (SaMD). Digital therapy is a subset of digital health. It includes evidence-based therapeutic interventions driven by high-quality software. Consequently intended to treat, manage or prevent a medical disorder or disease. Digital therapy is an algorithm-based, high-quality computer software that is often operated by artificial intelligence. It provides treatment for a disease, partially replacing the work of human specialists.

A feasibility study of the “Vigo” product has already been carried out in collaboration with RSU in 2020. It involved stroke survivors who provided strong positive feedback on the benefit of “Vigo” in their rehabilitation process.